<DOC>
	<DOCNO>NCT00744445</DOCNO>
	<brief_summary>The purpose research study determine activity erythropoietin ( r-HuEPO ) time dependent give chronic renal failure patient three different time day .</brief_summary>
	<brief_title>Erythropoietin Therapy Patients With Chronic Renal Failure : A Study Time Dependent Activity</brief_title>
	<detailed_description>This phase-II crossover study design test activity erythropoietin time dependent . Patients chronic renal failure hemodialysis require r-HuEPO maintain adequate level hematocrit eligible study . Patients administer r-HuEPO subcutaneously three time per week , 50 U/kg , round near 2000 unit . r-HuEPO administer hematocrit rise baseline level 20-24 % target level 30-34 % . This repeat three time , different time day , either 0800 , 1500 2200 hr order randomly determine . Each patient complete three phase .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Chronic renal failure patient require hemodialysis require rHuEPO maintain adequate hematocrit level Serum ferritin level &gt; 200 micrograms/L transferrin saturation &gt; 15 % Serum erythropoietin level le 500 mu/ml ( rHuEPO ) Prior therapy rHuEPO An adequate program dialysis establish Informed consent sign Adocumented cause anemia chronic renal disease Symptoms unstable coronary artery disease Poorly control hypertension Known seizure disorder Other active inflammatory infective disorder Other disorder may diminish response bone marrow rHuEPO</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>erythropoietin</keyword>
</DOC>